EAM
TPST icon

Eagle Asset Management’s Tempest Therapeutics TPST Stock Holding History

Eagle Asset Management’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-4
Closed -$9K – 647
2018
Q2 		$9K Hold
4
– – ﹤0.01% 617
2018
Q1 		$8K Buy
+4
New +$12K ﹤0.01% 625

Other funds holding TPST

PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Eagle Asset Management's TPST Position: Q3 2018 in Review

Eagle Asset Management sold out of Tempest Therapeutics (TPST) in Q3 2018, closing a stake of 4 shares — an estimated $9K sold.

Eagle Asset Management first reported a position in TPST in Q1 2018 and held it in 2 quarters. The position peaked at $9K in Q2 2018. 35 funds tracked by Wall St. Rank hold TPST as of Q3 2018.

  • Eagle Asset Management reported no remaining Tempest Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Eagle Asset Management sold 4 Tempest Therapeutics shares in Q3 2018, an estimated $9K.
  • Eagle Asset Management first reported a position in Tempest Therapeutics in Q1 2018 and held it in 2 quarters.
  • Eagle Asset Management's Tempest Therapeutics position peaked at $9K in Q2 2018.
  • 35 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q3 2018.

Based on Eagle Asset Management's 13F filing for Q3 2018, filed 8 Nov 2018.